Top

Published in:

Open Access 01-12-2020 | Tocilizumab | Letter

COVID-19: room for treating T cell exhaustion?

Authors: Giovanni Riva, Vincenzo Nasillo, Enrico Tagliafico, Tommaso Trenti, Mario Luppi

Excerpt

Dear Editor, …

Cao X. COVID-19: immunopathology and its implications for therapy. Nat Rev Immunol. 2020:1–2. https://doi.org/10.1038/s41577-020-0308-3. [Epub ahead of print] PMCID: PMC7143200.

Ritchie AI, Singanayagam A. Immunosuppression for hyperinflammation in COVID-19: a double-edged sword? Lancet. 2020;395(10230):1111. https://doi.org/10.1016/S0140-6736(20)30691-7. PMID: 32220278.CrossRefPubMedPubMedCentral

Qin C, Zhou L, Hu Z, et al. Dysregulation of immune response in patients with COVID-19 in Wuhan, China. Clin Infect Dis. 2020. https://doi.org/10.1093/cid/ciaa248. [Epub ahead of print] PMID: 32161940.

Moon C. Fighting COVID-19 exhausts T cells. Nat Rev Immunol. 2020:1. https://doi.org/10.1038/s41577-020-0304-7. [Epub ahead of print] PMCID: PMC7132550.

Shankar-Hari M, Fish M, Azoulay E. Should we consider blocking the inhibitory immune checkpoint molecules for treating T cell exhaustion in sepsis? Intensive Care Med. 2020;46(1):119–21. https://doi.org/10.1007/s00134-019-05814-8. PMID: 31659386.CrossRefPubMed

Title: COVID-19: room for treating T cell exhaustion?
Authors: Giovanni Riva
Vincenzo Nasillo
Enrico Tagliafico
Tommaso Trenti
Mario Luppi
Publication date: 01-12-2020
Publisher: BioMed Central
Keywords: Tocilizumab
COVID-19
Checkpoint Inhibitors
Published in: Critical Care / Issue 1/2020
Electronic ISSN: 1364-8535
DOI: https://doi.org/10.1186/s13054-020-02960-0